Novartis Expands Oncology Portfolio with US$1.5 B Acquisition of Myricx
By Sanya Sekhri
Pharma Deals Review: Vol 2026 Issue 8 (Table of Contents)
Published: 1 Aug-2026
DOI: 10.3833/pdr.v2026.i8.3029 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a strategic move to strengthen its oncology portfolio, Novartis has agreed to acquire Myricx for approximately US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
PharmaDeals will be moved to a new platform by October 31, 2026. Please look out for an email from your IQVIA account manager by the end of September with details.
RSS